Deutsche Bank AG reaffirmed their buy rating on shares of BTG plc (LON:BTG) in a research note published on Thursday morning, MarketBeat reports. They currently have a GBX 775 ($10.45) price target on the stock.
BTG has been the topic of a number of other reports. Numis Securities Ltd reiterated a buy rating and issued a GBX 900 ($12.13) price objective on shares of BTG plc in a research report on Thursday, July 13th. Peel Hunt reiterated a hold rating and issued a GBX 680 ($9.17) price objective on shares of BTG plc in a research report on Wednesday, September 20th. J P Morgan Chase & Co reiterated a neutral rating and issued a GBX 790 ($10.65) price objective on shares of BTG plc in a research report on Tuesday, July 4th. Stifel Nicolaus reiterated a buy rating and issued a GBX 800 ($10.79) price objective on shares of BTG plc in a research report on Wednesday, August 30th. Finally, Shore Capital reiterated a not rated rating on shares of BTG plc in a research report on Thursday, July 13th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of GBX 780.33 ($10.52).
Shares of BTG plc (LON BTG) opened at 672.00 on Thursday. The company’s market cap is GBX 2.59 billion. BTG plc has a 1-year low of GBX 528.36 and a 1-year high of GBX 738.50. The stock has a 50 day moving average price of GBX 672.19 and a 200-day moving average price of GBX 655.00.
TRADEMARK VIOLATION WARNING: “BTG plc (BTG) Stock Rating Reaffirmed by Deutsche Bank AG” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://baseballnewssource.com/markets/btg-plc-btg-stock-rating-reaffirmed-by-deutsche-bank-ag/1666961.html.
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with our FREE daily email newsletter.